DETAILED ACTION
Applicant’s response, filed 30 Sept. 2026 has been fully considered. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Claims
Claims 1, 3-10, 12, 15-24, 26-30, 34-36, 38, 40-45 are cancelled.
Claim 49 is newly added.
Claims 2, 11, 13-14, 25, 31-33, 37, 39, and 46-49 are pending.
Claims 2, 11, 13-14, 25, 31-33, 37, 39, and 46-49 are rejected.
Claim 47 is objected to.
Priority
The effective filing date of the claimed invention is 24 March 2017.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 30 Sept. 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the list of cited references was considered in full by the examiner.
Claim Interpretation
Independent claim 25 recite “targets”. Applicant’s specification at para. [0103] defines the word “target” to refer to a composition which can be associated with a barcode, including oligonucleotides, DNA, mRNA, microRNA, tRNA, etc. Therefore, the term target is interpreted to mean the entity to which the barcode can be attached (e.g. an RNA molecule).
Claim 25 recites “(a) obtaining, with the computer system, gene expression data comprising a plurality of mRNA expression profiles of a plurality of cells in a sample”, which is interpreted to mean a computer system receives (i.e. obtains) already generated gene expression data comprising mRNA expression profile. The claim does not require generating the gene expression data from the sample. Dependent claims 47-48 recite “wherein the occurrence…is obtained by sequencing…” and “wherein the plurality of mRNA expression profiles is obtained by sequencing and/or digital PCR”, which is interpreted to define the process in which the gene expression data received by the computer system of claim 25 was previously generated. However, the claims do not require a step of generating the mRNA expression profiles by performing sequencing and/or digital PCR.
Claim 14 recites “…wherein the one or more expression profiles…used in training the machine learning model comprises a percentage of the plurality of expression profiles determined in (b)”, respectively. Claim 14 is interpreted to mean that the one or more expression profiles used in training comprise less than the total number of the plurality of expression profiles determined in (b).
Response to Arguments
Applicant's arguments filed 30 Sept. 2026 regarding the claim interpretations have been fully considered but they are not persuasive.
Applicant remarks that Applicant does not necessarily agree with the interpretations and that claims are to be given their broadest reasonable interpretation (Applicant’s remarks at pg. 6, para. 2).
This argument is not persuasive because While Examiner agrees that generally claims are to be given their broadest reasonable interpretation consistent with the specification, where an explicit definition is provided by the applicant for a term, that definition will control interpretation of the term as it is used in the claim. See MPEP 2111. It is noted that Applicant’s specification defines the term “target” as indicated above, and therefore this term does not receive the broadest reasonable interpretation of the term “target”.
Claim Objections
Claim 47 is objected to because of the following informalities. This objection is newly recited and necessitated by claim amendment.
Claim 47 recites “using plurality of target specific primers…” in lines 2-3, which is missing an article before plurality and should recite “using a plurality of target specific primers…”.
Appropriate correction is required.
Claim Rejections - 35 USC § 112(b)
The previous rejection of claims 2, 11, 13-14, 25, 31-33, 37, 39, and 46-48 in the previous Office action mailed 02 June 2026 under 35 U.S.S. 112(b) has been withdrawn in view of claim amendments received 30 Sept. 2026.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 2, 11, 13-14, 25, 31-33, 37, 39, and 46-49 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. Any newly recited portion herein is necessitated by claim amendment.
The Supreme Court has established a two-step framework for this analysis, wherein a claim does not satisfy § 101 if (1) it is “directed to” a patent-ineligible concept, i.e., a law of nature, natural phenomenon, or abstract idea, and (2), if so, the particular elements of the claim, considered “both individually and as an ordered combination,” do not add enough to “transform the nature of the claim into a patent-eligible application.” Elec. Power Grp., LLC v. Alstom S.A., 830 F.3d 1350, 1353 (Fed. Cir. 2016) (quoting Alice, 134 S. Ct. at 2355). Applicant is also directed to MPEP 2106.
Step 1: The instantly claimed invention (claim 25 being representative) is directed a method for identifying a multiplet expression profile. Therefore, the instantly claimed invention falls into one of the four statutory categories. [Step 1: YES]
Step 2A: First it is determined in Prong One whether a claim recites a judicial exception, and if so, then it is determined in in Prong Two if the recited judicial exception is integrated into a practical application of that exception.
Step 2A, Prong 1: Under the MPEP § 2106.04, the Step 2A (Prong 1) analysis requires determining whether a claim recites an abstract idea, law of nature, or natural phenomenon.
Independent claim 25 recites the following steps which fall under the mental processes groupings of abstract ideas:
(b) generating…. a plurality of synthetic multiplet expression profiles from the plurality of mRNA expression profiles of the plurality of cells, comprising: for each synthetic multiplet expression profile of the plurality of synthetic multiplet expression profiles, (1) selecting at least two expression profiles of the plurality of expression profiles; and (2) for each of the plurality of genes, combining occurrences of the target in the expression profiles selected in (1) into a combined occurrence of the target to generate the synthetic multiplet expression profile, wherein the synthetic multiplet expression profile is in the expression profile space;
(c) identifying among the plurality of mRNA expression profiles at least one multiplet expression profile by:
projecting…each synthetic multiplet expression profile of the plurality of synthetic multiplet expression profiles generated in (b) from the expression profile space into a lower dimensional projection space to generate projected synthetic multiplet expression profiles;
projecting, with the computer system, one or more mRNA expression profiles of the plurality of mRNA expression profiles from the expression profile space into the lower dimensional projection space to generate one or more projected mRNA expression profiles, wherein the multiplet expression profile is identified based on the proximity of a projected mRNA expression profile associated with a cell label among the one or more projected mRNA expression profiles and one or more of the plurality of projected synthetic multiplet expression profiles in the lower dimensional projection space;
(d) removing… the at least one multiplet expression profile identified in (c) from the gene expression data obtained in (a), thereby generating second gene expression data comprising singlet mRNA expression profiles corresponding to a tissue of the different tissues and/or to a cell type of the plurality of cell types in the sample.
The identified claim limitations falls into the group of abstract ideas of mental processes for the following reasons. First, the steps of generating a plurality of synthetic multiplet expression profiles involves selecting at least two expression profiles and then combining the at least two of the expression profiles (e.g. by taking an average expression of each of 2 or more genes), which can be practically performed in the mind aided with pen and paper. The steps of identifying an expression profile as a multiplet based on determining a proximity of a projected expression profile with a projected synthetic profile in an expression profile space can be practically performed in the mind by comparing distances of the expression profile to the synthetic multiplet expression profile in a projected space (e.g. a two-dimensional space on an x-y axis) to determine if the expression profile is a singlet or multiplet. The step of removing the identified at least one multiplet from the gene expression data can be practically performed in the mind by analyzing the plurality of expression profiles to remove any profiles, or sequences associated with the profiles, identified to be a multiplet, thereby leaving a plurality of singlet expression profiles, which can be practically performed in the mind. Therefore, these limitations recite a mental process. See MPEP 2106.04(a)(2) III.
In addition, the limitations of generating synthetic multiplet expression profiles by combining occurrences of a target in at least two expression profiles and identifying an expression profile as a multiplet based on a proximity of the expression profile to synthetic multiplet profiles in an expression profile space, projecting each multiplet expression profile into a lower dimensional projection space to generate projected multiplet expression profiles, projecting one or more RNA expression profiles from the expression profile space into the lower dimensional projection space to generated projected mRNA expression profiles, and identifying the at least one multiplet expression profile based on the proximity of a projected mRNA expression profile to a projected synthetic multiplet expression profile in the lower dimensional space further recite a mathematical concept. First, combining occurrences of two expression profiles amounts to a textual equivalent to summing two numbers, which is a mathematical calculation. First, combining occurrences of two expression profiles amounts to a textual equivalent to summing two numbers, which is a mathematical calculation. Similarly, the identifying step encompasses mathematical dimensionality reduction, as discussed in Applicant’s specification (see para. [0068]) and also recited in dependent claim 46, which discloses projecting the data into a lower-dimensional space using t-distributed stochastic neighbor embedding and calculating distances to determine the proximity between an expression profile and the synthetic profiles in an expression profile space, which is a statistical method that requires calculating distances between each datapoint. In other words, the above limitations amount to a textual equivalent to performing mathematical calculations, and thus recite a mathematical concept as set forth in MPEP 2106.04(a)(2) I. C.
Dependent claims 2, 11, 13-14, 31-33, 39, 46, and 49 further recite an abstract idea and/or further limit the abstract idea of the independent claims above. Dependent claim 2 further limits the mental process of generating the synthetic multiplet expression profiles to comprise a doublet or triplet. Dependent claim 11 further recites the mental process of selecting a number of expression profiles as a number of 1-10 percent of the plurality of expression profiles determined in (b). Dependent claim 31 further recites the mental process of combining a number of labels with distinct sequences associated with a target in at least two expression profiles to generate a number of molecular labels for the synthetic multiplet expression profile. Dependent claim 32 further recites the mental process and mathematical concept of determining a sum of the occurrences of the target or molecular labels, respectively, in the expression profiles selected. Dependent claim 32 further recites the mental process and mathematical concept of determining a weighted sum of the occurrences of the target or the number of molecular labels, respectively, in the expression profiles selected. Dependent claim 32 further recites the mental process and mathematical concept of determining an average or weighted average of the number of molecular labels in the selected expression profiles. Dependent claims 13 and 33 further recites the mental process and mathematical concept of training a machine learning model for expression profile multiplet identification from the expression profiles of the plurality of synthetic multiplet expression profiles and one or more expression profiles of the plurality of expression profiles, given training a machine learning model encompasses performing an unsupervised clustering analysis (i.e. a k-nearest neighbor model, as discussed at para. [0031] of Applicant’s specification), which amounts to a textual equivalent to performing mathematical calculations (e.g. calculating distances between points); claims 13 and 33 further recite the mental process and mathematical concept of identifying the expression profile of the plurality of expression profiles associated with a cell of the plurality of cell as a singlet or a multiplet based on the expression profile using the machine learning model. Dependent claim 14 further limits the mental process and mathematical concept of training the machine learning model to use a percentage of the plurality of expression profiles. Dependent claim 36 further recites the mental process of selecting a number of expression profiles in a range of 2-20. Dependent claim 6 further limits the projecting to use the mathematical process of a t-distributed stochastic neighbor embedding (tSNPE) to perform the projection. Dependent claim 39 further limits the method to comprise not analyzing a sample tag to distinguish between mRNA molecules from different tissue types and/or cell types. Dependent claim 49 further limits the mental process and mathematical concept of generating synthetic multiplet expression profiles to comprise combining occurrences of mRNA molecules for each of 96 genes into a combined occurrence value. Therefore, claims 2, 11, 13-14, 25, 31-33, 37, 39, and 46-49 recite an abstract idea. [Step 2A, Prong 1: YES]
Step 2A: Prong 2: Under the MPEP § 2106.04, the Step 2A, Prong 2 analysis requires identifying whether there are any additional elements recited in the claim beyond the judicial exception(s), and evaluating those additional elements to determine whether they integrate the exception into a practical application of the exception.
Claims 2, 11, 13-14, 31-33, 46, and 49 do not recite any elements in addition to the recited judicial exception and thus are part of the judicial exception.
The additional elements of independent claim 25 include:
(b) obtaining, with a computer system, gene expression data comprising a plurality of mRNA expression profiles of a plurality of cells in a sample wherein the sample comprises cells from different tissues or a plurality of cell types, wherein each mRNA expression profile of the plurality of mRNA expression profiles: comprises an occurrence of mRNA molecules of a plurality of genes, is in an expression profile space, and is associated with a cell label that is unique among the plurality of mRNA expression profiles (i.e. receiving data); and
with the computer system (steps (b) and (d)).
The additional elements of claim 37 and 47-48 include:
wherein the sample comprises peripheral blood mononuclear cells (PBMC) and/or circulating tumor cells (claim 37);
where in the occurrence of mRNA molecules of the plurality of genes is obtained by sequencing amplicons generated using a plurality of target specific primers to amplify labeled cDNA molecules of the mRNA molecules of the plurality of genes (claim 47); and
wherein the plurality of mRNA expression profiles is obtained by sequencing and/or digital PCR (claim 48).
The additional elements of claim 25 of receiving data by a computer, and a computer that carries out the abstract idea are generic computer components and functions. The additional elements of claims 37 and 47-48 only serve to further limit the data being received by the computer in claim 25, and therefore are part of the additional element of using a computer to receive data. The courts have found the use of a computer or other machinery in its ordinary capacity for economic or other tasks (e.g., to receive, store, or transmit data) or simply adding a general purpose computer or computer components after the fact to an abstract idea (e.g., a fundamental economic practice or mathematical equation) does not integrate a judicial exception into a practical application. See MPEP 2106.05(f).
Furthermore, the additional elements of obtaining, by a computer, gene expression data generated by sequencing and/or digital PCR and target specific primers from a sample containing PBMC and/or circulating tumor cells only serve to collect sequencing and expression data for use by the abstract idea of generating synthetic multiplet expression profiles and ultimately identifying a multiplet expression profile, which amounts to necessary data gathering and does not integrate the recited judicial exception into a practical application. See MPEP 2106.05(g).
Last, while Applicant’s specification at para. [0003] and [0208]] discloses detected expression profiles may be associated with two or more cells, which skews interpretation of the expression profile, and the disclosed methods are for identifying a multiplet expression profile using synthetic multiplet expression profiles, the specification does not provide a technical explanation regarding how the additional elements provide an improvement to technology. Instead, the disclosed improvement amounts to an improved analysis of sequencing data (i.e. an un-skewed interpretation), which is not an improvement to technology.
Therefore, the additionally recited elements amount to mere instructions to apply the exception on a computer and/or amount to insignificant extra-solution activity and, as such, the claims as a whole do no integrate the abstract idea into practical application. See MPEP 2106.05(g). Thus, claims 2, 11, 13-14, 25, 31-33, 37, 39, and 46-49 are directed to an abstract idea. [Step 2A, Prong 2: NO]
Step 2B: In the second step it is determined whether the claimed subject matter includes additional elements that amount to significantly more than the judicial exception. See MPEP § 2106.05.
The claims do not include any additional steps appended to the judicial exception that are sufficient to amount to significantly more than the judicial exception.
Claims 2, 7-8, 11, 13-14, 23-24, 28, 31-33, 36, 41-46, and 49 do not recite any elements in addition to the recited judicial exception and thus are part of the judicial exception.
Claims 25, 37, and 47-48 recite the additional elements identified above.
The additional elements of claim 25 of receiving data by a computer, and a computer that carries out the abstract idea are conventional computer components and functions. The additional elements of claims 37-47-48 only serve to further limit the data being received by the computer in claim 25, and thus are part of the additional element of receiving data. The courts have found the use of a computer or other machinery in its ordinary capacity for economic or other tasks (e.g., to receive, store, or transmit data) or simply adding a general purpose computer or computer components after the fact to an abstract idea (e.g., a fundamental economic practice or mathematical equation) does not provide significantly more. See Affinity Labs v. DirecTV, 838 F.3d 1253, 1262, 120 USPQ2d 1201, 1207 (Fed. Cir. 2016) (cellular telephone); TLI Communications LLC v. AV Auto, LLC, 823 F.3d 607, 613, 118 USPQ2d 1744, 1748 (Fed. Cir. 2016) (computer server and telephone unit).
Therefore, the additional elements do not amount to significantly more than the above-identified judicial exception(s). Even when viewed as a combination, the additional elements fail to transform the exception into a patent-eligible application of that exception. Thus, the claims as a whole do not amount to significantly more than the exception itself. [Step 2B: NO]
Therefore, the instantly rejected claims are not drawn to eligible subject matter as they are directed to an abstract idea without significantly more. For additional guidance, applicant is directed generally to applicant is directed generally to the MPEP § 2106.
Response to Arguments
Applicant's arguments filed 30 Sept. 2026 regarding 35 U.S.C. 101 have been fully considered but they are not persuasive.
Applicant remarks that a claim reciting a judicial exception is not directed to the judicial exception if it also recites additional elements demonstrating the claim as whole integrates the judicial exception into a practical application, including improving a technical field, and further remarks claim 25 as a whole represents an improvement in a technical field by providing a process for analyzing gene expression data that mitigates skewed interpretation of expression profiles, and thereby generates a more accurate representation of cellular diversity in a sample (Applicant’s remarks at pg. 6, para. 5 to pg. 7, para. 2). Applicant remarks the Application describes a solution to the problem of single-cell expression procedures generating multiple expression profiles of generating synthetic multiplet profiles from experimentally obtained data, identifying multiplet profiles based on the proximity of each profile with the synthetic multiplet profile, and removing the identified multiplet profiles from the profile data, and further remarks this result can be achieved without prior knowledge of location of each tissue or cell type in a profile space such that the invention can be implemented without prior knowledge of the number of tissue or cell types in the sample (Applicant’s remarks at pg. 7, para. 3 to pg. 8, para. 2). Applicant further remarks the invention represents the position of various profiles in a dimensional space that help visualize the distribution of profiles and facilitate determining the relative distance of each profile to other profiles, and furthermore, that the claimed methods recite a combination of features that mitigate interpretation of expression data, including technical features of generating synthetic expression profiles, identifying a multiplet expression profile from the mRNA expression profiles, and removing the at multiplet expression profile from the gene expression data (Applicant’s remarks at pg. 8, para. 3 to pg. 9, para. 2).
This argument is not persuasive. It is important to keep in mind that an improvement in the abstract idea itself (e.g. a recited fundamental economic concept) is not an improvement in technology. Furthermore, It is important to note, the judicial exception alone cannot provide the improvement. The improvement can be provided by one or more additional elements or by the additional element(s) in combination with the recited judicial exception. See MPEP 2106.05(a).
In the instant case, Applicant argues the solution to the technical problem of multiplet profiles is provided by analyzing mRNA expression data, including steps (b)-(d) of generating the synthetic profiles, identifying a multiplet profile by projection synthetic profiles into a lower dimensional space, and removing the identified multiplet profile from the mRNA expression data. Each of steps (b)-(d) is part of the abstract idea, and Applicant has not provided an explanation for how any additional element(s) in the claim provide the alleged improvement in analyzing expression data. Furthermore, an improvement in the analysis if mRNA expression data amounts to an improvement in the abstract idea itself, which is not an improvement to technology as set forth in MPEP 2106.05(a). Each of Applicant’s arguments describing the alleged improvement include providing an accurate picture of mRNA expression profiles in the data by removing multiplet profiles, visualizing distribution profiles, and mitigating skewed interpretation of data are similarly improvements in an abstract idea, rather than a non-abstract technology.
Therefore, while Applicant states the claims solve the technical problem relating to multiplet expression profile generating during single cell assays, the technical solution discussed by Applicant is merely an improvement in the analysis of obtained gene expression data that provides more accurate single-cell expression information (i.e. an improvement in the abstract idea), rather than any improvement in the assay itself, provided by additional elements, that reduces multiplet profile formation. Thus, the claims do not recite additional elements that integrate the recited judicial exception into a practical application of an improvement to technology.
Applicant remarks that the Examiner asserts in the previous Office action that the previous remarks related to technological improvement is not commensurate in scope on the grounds that claim 25 does not require the mRNA expression profiles were generated by single-cell mRNA sequencing, however Applicant submits that one of ordinary skill in the art would recognize that each mRNA expression profile being associated with a cell label that is unique among mRNA expression profiles provides a way to trace each expression profile to a single cell, and one would readily recognize that the present Application addresses the general problem that arises when there is a break down in one to one correspondence between a cellular profile associated with a cell label and the unique cells source (Applicant’s remarks at pg. 10, para. 1-2).
This argument is not persuasive. First, it was not alleged that the claims do not generate single cell expression profiles. The prior Office action stated that claim 25 “does not require the mRNA expression profiles were generated by single-cell sequencing (e.g. as opposed to digital PCR)” (see para. [063] of the Office action mailed 02 June 2026). In other words, it is agreed that the gene expression profiles of the claims are single-cell profiles; however, they are not required to be single cell sequencing expression profiles.
Furthermore, for the reasons set forth above, the claims do not reflect an improvement to technology, regardless of whether the single cell gene expression profiles were determined by single cell sequencing.
Applicant remarks claim 49 is allowable for similar reasons as set forth above (Applicant’s remarks at pg. 10, para. 3).
This argument is not persuasive for the same reasons set forth above.
Response to Affidavit
The affidavit under 37 CFR 1.132 filed 30 Sept. 2026 is insufficient to overcome the rejection of claims 2, 11, 13-14, 25, 31-33, 37, 39, and 46-49 based upon 35 U.S.C. 101 as set forth in the last Office action because:
Applicant remarks the Application describes a technical solution to problems that arise when using single cell-based techniques for profiling cellular phenotypes, and the claims provide an improvement to technology compared to conventional processes and provide a more accurate assessment of tissue or cellular diversity in a sample by mitigating skewed interpretation of cellular profiles, such as expression profiles (Applicant’s remarks at pg. 1, para. 3; see point 3). Applicant remarks that practitioners now can profile cellular phenotypes at the single cell level, and a common source of experimental variability and noise in single-cell profiling is the formation of doublet and multiplet profiles, and further remarks the Application provides an in silico solution to this problem by projecting expression profiles into a lower dimensional space, identifying multiplet profiles based on the proximity of each profile with synthetic multiplet profiles, and removing identified multiplet profiles from the data, which is less susceptible to sample-sample variation and can be implemented without prior knowledge of a number of cell types expected in a sample (Applicant’s remarks at pg. 1, para. 4 to pg. 2, para. 3: see points 4-6).
This argument is not persuasive for the same reasons discussed above. It is important to keep in mind that an improvement in the abstract idea itself (e.g. a recited fundamental economic concept) is not an improvement in technology. Furthermore, It is important to note, the judicial exception alone cannot provide the improvement. The improvement can be provided by one or more additional elements or by the additional element(s) in combination with the recited judicial exception. See MPEP 2106.05(a).
In the instant case, Applicant argues the solution to the technical problem of multiplet profiles is provided by analyzing mRNA expression data, including steps (b)-(d) of generating the synthetic profiles, identifying a multiplet profile by projection synthetic profiles into a lower dimensional space, and removing the identified multiplet profile from the mRNA expression data. Each of steps (b)-(d) is part of the abstract idea, and Applicant has not provided an explanation for how any additional element(s) in the claim provide the alleged improvement in analyzing expression data. Furthermore, an improvement in the analysis of mRNA expression data amounts to an improvement in the abstract idea itself, which is not an improvement to technology as set forth in MPEP 2106.05(a).
Therefore, the technical solution discussed by Applicant is merely an improvement in the analysis of obtained gene expression data that provides more accurate single-cell expression information (i.e. an improvement in the abstract idea), rather than any improvement in the assay itself, provided by additional elements, that reduces multiplet profile formation. Thus, the claims do not recite additional elements that integrate the recited judicial exception into a practical application of an improvement to technology.
Applicant further remarks: removing identified multiplet profiles provides a more accurate picture of diversity of profiles in the data and prevents or minimizes skewed interpretation of the expression profile of the sample; projecting profiles into lower-dimensional space helps visualize the distribution of profiles and facilitates determining the distance of each profile to other profiles and to synthetic profiles; and the combination of features including generating synthetic multiplet expression profiles and identifying multiplet expression profiles as recited in the claims represents a technological improvement that results in more accurate representation of diversity of cell types in gene expression data (Applicant’s remarks at pg. 2, para. 4 to pg. 4, para. 1 and ; see points 4-11).
This argument is not persuasive. Each of Applicant’s arguments describing the alleged improvement include providing an accurate picture of mRNA expression profiles in the data by removing multiplet profiles, visualizing distribution profiles, and mitigating skewed interpretation of data are similarly improvements in an abstract idea, rather than a non-abstract technology. Accordingly, the claims do not reflect an improvement to technology as set forth in MPEP 2106.05(a).
Conclusion
No claims are allowed.
Claims 2, 11, 13-14, 25, 31-33, 37, 39, and 46-49 are free of the prior art for the reasons discussed in the Office action mailed 23 Nov. 2021.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Inquiries
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAITLYN L MINCHELLA whose telephone number is (571)272-6485. The examiner can normally be reached 7:00 - 4:00 M-Th.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Olivia Wise can be reached at (571) 272-2249. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/KAITLYN L MINCHELLA/Primary Examiner, Art Unit 1685